Down Syndrome
A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
Drugs by status
Phase 4 trials (4)
Phase 3 trials (28)
- tioguanine
- mercaptopurine
- aldoxorubicin
- vitamin e
- urea
- blinatumomab
- prednisone
- doxorubicin
- naltrexone
- idarubicin
- levetiracetam
- leucovorin
- vincristine
- pegaspargase
- donepezil
- caffeine
- cyclophosphamide
- daunorubicin
- methotrexate
- erwinia asparaginase
- multivitamins
- etoposide
- prednisolone
- cytarabine
- asparaginase
- mitoxantrone
- dexamethasone
- mk 6240
Phase 2 trials (27)
- sodium fluoride (18F)
- florbetaben F-18
- aci-24
- porcine brain-derived peptide preparation
- tofacitinib
- methylphenidate
- sevoflurane
- scyllo-inositol
- guanfacine
- hydrocortisone
- epirubicin
- nivolumab
- lorazepam
- oxybutynin
- nicotine
- basmisanil
- immune globulin (human)
- rivastigmine
- desflurane
- ubiquinol
- l-epigallocatechin
- atomoxetine
- bumetanide
- oxygen
- sargramostim
- aef0217
- [18f]-feobv
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (23)
- Eisai
- Pfizer
- Ascopharm Groupe Novasco
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute on Aging (NIA)
- Georgetown University
- Institut Jerome Lejeune
- Rutgers University
- University of Kansas
- University of Michigan
- Columbia University
- University of California, San Diego
- Icahn School of Medicine at Mount Sinai
- University of Limoges
- University of Paris
- Department of Veteran Affairs
- Eurofins
- State of New York
- Effi-stat
- AnticipSante
- BIOMNIS
Organization Involved with Phase 2 Indications (25)
- AC Immune SA
- Roche
- Elan Pharmaceuticals
- Bayer
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Piramal
- Transition Therapeutics
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Arizona
- Case Western Reserve University
- Duke University
- Johns Hopkins University
- University of Southern California
- University of California, Davis
- University of Cincinnati
- Vanderbilt University
- GH Asklepieio Voulas
- Asklepieion General Hospital
- National University of Singapore
- National Hospital Organisation Nagoya Medical Centre
- Universidad Autonoma de San Luis Potosi
- Alana USA Foundation
- Taishoff Family Foundation
- Institut Hospital del Mar d'Investigacions Mèdiques
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (13)
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of Pennsylvania
- Cairo University
- University of London
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
- University of Exeter
- University of Lausanne
- National Taiwan University
- University of Oxford
- University of Sao Paulo
- Northgate and Prudhoe NHS Trust
- University of Cantabria
- Instituto Hispalense de Pediatría, Sevilla, Spain